Minghui Sun

Minghui Sun


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

30 August 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YQYuling Qin
Yuling Qin
CXChuyao Xiao
Chuyao Xiao
XLXiaoyue Li
Xiaoyue Li
JHJiangeng Huang
Jiangeng Huang
LSLuqin Si
Luqin Si
MSMinghui Sun
Minghui Sun
The pH–induced crystallization of weakly basic drugs in the small intestine limits oral bioavailability. In this study, we investigated the solubilization and inhibitory effects on nintedanib in the presence of enteric polymers (HPMCAS LG, HPMCAS MG, Eudragit L100 55, and Eudragit L100). These polymers provided maintenance of supersaturation by increasing the solubility of nintedanib in PBS 6.8 in a concentration-dependent manner, and the improved ranking was as follows: Eudragit L100 > Eudragit L100 55 > HPMCAS MG > HPMCAS LG. After being formulated into amorphous solid dispersions (ASDs) by a solvent evaporation method, the drug exhibited an amorphous state. The pH shift dissolution results of polymer-ASDs demonstrated that four polymers could effectively maintain the drug supersaturation even at the lowest ratio of nintedanib and polymer (1:1, w/w). Eudragit L100–ASD could provide both acid resistance and the favorable mitigation of crystallization in GIF. In comparison to the coarse drug, the relative bioavailability of Eudragit L100–ASD was 245% after oral administration in rats, and Tmax was markedly delayed from 2.8 ± 0.4 h to 5.3 ± 2.7 h. Our findings indicate that enteric ASDs are an effective strategy to increase the intestinal absorption of nintedanib by improving physiologically generated supersaturation and subsequent crystallization.

1 December 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
LQLihui Qiu
Lihui Qiu
QLQian Li
Qian Li
JHJiangeng Huang
Jiangeng Huang
QWQi Wu
Qi Wu
KTKun Tu
Kun Tu
LSLuqin Si
Luqin Si